ArticleMolecular and cellular biochemistry2026
Dapagliflozin attenuates methotrexate-induced hepatorenal toxicity in rats: insights into oxidative stress, inflammation, autophagy and apoptosis.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is a potent chemotherapeutic drug used to treat various malignancies, and serious autoimmune diseases. Unfortunately, the potential liver and kidney toxicities of MTX restrict its clinical effectiveness. The present study aims to explore the protective effects of dapagliflozin (Dapa) against MTX-induced hepatorenal toxicity in a rat model. Eighteen male Sprague-Dawley rats were randomly distributed into three groups; Normal, MTX and MTX + Dapa, rats received Dapa (10 mg/kg) orally once daily for 10 days; and a single i.p. injection of MTX (20 mg/kg) on the fifth day. The Dapa ameliorated hepatorenal histopathological changes induced by MTX and modulated liver and kidney function biomarkers. Dapa significantly upregulated the expression of PPAR-γ /Nrf-2/HO-1 which in turn downregulated the expression of NF-κB in hepatic and renal sections. Also, Dapa restored hepatic and renal tissues oxidative balance via significant elevation of GSH content and lowering MDA content. Moreover, Dapa modulated beclin1/LC3 dependent autophagy and caspase-3/Bcl-2 mediated apoptosis in hepatic and renal tissues. In conclusion, Dapa showed substantial hepatorenal protection against MTX-induced hepatorenal toxicity, highlighting a new therapeutic strategy in MTX treatment protocols.
Indexed as
Identifiers
42742853What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.